STAGE III RENAL CELL CANCER AJCC V8

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The dr…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This phase 2 trial tests whether adding a live bacteria product called CBM588 to the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. About 62 adults with high-risk clear cell or sarcomatoid kidney cancer will receive either pembroli…

This phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…

This early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the s…

This study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immuno…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests whether adding inulin gel, a fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with metastatic or locally advanced clear cell or sarcomatoid kidney cancer will take part. Research…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…